CGEM trades 98.6% below Wall Street's consensus target of $33.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CGEM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Cullinan Therapeutics, Inc. (CGEM) has a Wall Street consensus price target of $33.50, based on estimates from 8 covering analysts. With the stock currently trading at $16.87, this represents a potential upside of +98.6%. The company has a market capitalization of $1.04B.
Analyst price targets range from a low of $27.00 to a high of $40.00, representing a 39% spread in expectations. The median target of $33.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CGEM trades at a trailing P/E of -4.5x. Analysts expect EPS to grow +4.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.47 | $136.75 | +18.4% | Buy | — | 27 |
 RCUSArcus Biosciences, Inc. | $3.3B | $26.39 | $40.00 | +51.6% | Buy | — | 18 |
 PRCTPROCEPT BioRobotics Corporation | $1.0B | $18.09 | $22.13 | +22.3% | Buy | — | 16 |
 TPSTTempest Therapeutics, Inc. | $14M | $0.92 | — | — | — | — | — |
 AGENAgenus Inc. | $350M | $8.40 | $25.00 | +197.6% | Buy | 10.8x | 11 |
 NKTRNektar Therapeutics | $1.9B | $57.66 | $152.50 | +164.5% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 FATEFate Therapeutics, Inc. | $283M | $2.43 | $5.63 | +131.7% | Buy | — | 31 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.37 | $59.50 | +144.2% | Buy | — | 27 |
Quick answers to the most common questions about buying CGEM stock.
The consensus Wall Street price target for CGEM is $33.5, representing 98.6% upside from the current price of $16.87. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CGEM has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $33.5 implies 98.6% upside from current levels.
CGEM's current price is $16.87 with a consensus target of $33.5 (98.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for CGEM, while the most conservative target is $27. The consensus of $33.5 represents the median expectation. These targets typically reflect 12-month expectations.
CGEM is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CGEM stock forecast based on 8 Wall Street analysts shows a consensus price target of $33.5, with estimates ranging from $27 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CGEM, with a "Buy" consensus rating and $33.5 price target (98.6% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CGEM analyst price targets range from $27 to $40, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.